Dudley MP Ian Austin is calling on the government to think again about how treatments for Haemophilia sufferers are commissioned on the NHS.
Treatment for Haemophilia is currently provided by frequent injections of replacement engineered clotting factor concentrates. However, new longer lasting treatments are available that could be easier to use, allow patients to be more active, provide better protection from bleeds and reduce the occurrence of joint damage in the longer term.
Furthermore, a range of new treatments for haemophilia such as gene therapy and other novel therapies such as Emicizumab, Fitusiran and anti-TFPI inhibitors are expected to be licensed over the coming years.
Austin is concerned that the way NHS England will tender for and commission the treatments for haemophilia, which are heavily based on cost, will restrict access to these new developments.
He has signed a cross-party letter to Health Secretary Matt Hancock asking the government to look again at the way the NHS will commission treatments for Haemophilia A and B to make sure the patient is put first.
Ian Austin said:
“I’ve been contacted by constituents in Dudley who suffer from this rare disorder. It is a constant concern for them and their families as a small cut could lead to a bigger problem.
“Unfortunately, research shows that the UK spends the least and has the worst treatments outcomes in Europe. This is a serious problem which needs to be addressed.
“I want the government to look again at the way treatments are commissioned and tendered, so that the patient is the priority and the long-term health benefits are considered.
“This is exactly how politics should work. It’s my job to listen to my constituents and push for changes to help them.”